Akebia prices 25M-share public offering at $2.00/share, expects $46.5M net proceeds

Akebia Therapeutics, Inc.

Underwritten public offering of 25M shares at $2.00/share; gross proceeds $50M.
Net proceeds ~$46.5M (or ~$53.6M if underwriters' option exercised in full).
Underwriters granted 30-day option to purchase up to 3.75M additional shares.
Expected closing March 21, 2025; Leerink Partners and Piper Sandler lead.
Company states it is financed to achieve profitability under current operating plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.